AWHL (Aspira Womens Health) Research & Development: $3.13 Mil (TTM As of Mar. 2026)


AWHL Aspira Womens Health Inc AWHL
36 GF Score
Price $0.43
GF Value $0.28
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Aspira Womens Health Research & Development?

Aspira Womens Health AWHL +3.84% 36 Research & Development is $3.13 Mil as of Mar. 2026. GuruFocus rates AWHL with a GF Score™ of 36/100 and a GF Value™ of $0.28 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Aspira Womens Health's Research & Development for the three months ended in Mar. 2026 was $1.23 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $3.13 Mil.

Aspira Womens Health  (OTCPK:AWHL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Aspira Womens Health Research & Development Related Terms

Aspira Womens Health Research & Development Historical Data

* Premium members only.

The historical data trend for Aspira Womens Health's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aspira Womens Health Research & Development Chart

Aspira Womens Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.31 5.92 4.04 3.27 2.88

Aspira Womens Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.97 0.70 0.74 0.46 1.23
AWHL
36GF Score
Aspira Womens Health Inc AWHL
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aspira Womens Health Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $3.13 Mil mean?
Aspira Womens Health (AWHL) has a Research & Development of $3.13 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Aspira Womens Health and its competitors.
Is Aspira Womens Health's Research & Development too high?
Aspira Womens Health's current Research & Development is $3.13 Mil. Overall, Aspira Womens Health has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aspira Womens Health's Research & Development compare to BIOQ and MBAI?
Aspira Womens Health's Research & Development of $3.13 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Diagnostics & Research company?
A good Research & Development depends on the Medical Diagnostics & Research industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Aspira Womens Health and its competitors. Aspira Womens Health's current Research & Development is $3.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspira Womens Health stock overvalued right now?
Based on GuruFocus' analysis, Aspira Womens Health (AWHL) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $0.43 — trading 52.1% above its estimated fair value. The current Research & Development is $3.13 Mil. Aspira Womens Health's overall GF Score™ is 36/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Aspira Womens Health (AWHL), the current Research & Development is $3.13 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aspira Womens Health (AWHL) Overvalued in 2026?

Based on GuruFocus' analysis, Aspira Womens Health stock appears to be overvalued. The current stock price of $0.43 is trading 52.1% above its estimated GF Value™ of $0.28. GuruFocus considers Aspira Womens Health to be Significantly Overvalued.

Key valuation signals for AWHL:

  • Research & Development: $3.13 Mil
  • GF Value™: $0.28 vs. price of $0.43 (52.1% above fair value)
  • GF Score™: 36/100 with 7 warning signs

No single metric tells the full story. See the AWHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aspira Womens Health Business Description

Address 12117 Bee Caves Road, Suite 100, Building 3, Austin, TX, USA, 78738
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its main products include OvaWatch, Ova1Plus, Ova1, and Overa, which are used to assess ovarian cancer risk in women with adnexal masses. The company is also developing EndoCheck for endometriosis. The company views its operations and manages its business in a single operating segment, which is the discovery, development, and commercialization of noninvasive diagnostic tests.
36GF Score

Get the complete analysis for AWHL

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.43
Price
$0.28
GF Value